Meeting
2017 ASCO Annual Meeting
KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.
Authors
Matteo S. Carlino
Westmead and Blacktown Hospitals and Melanoma Institute Australia, Sydney, Australia
Matteo S. Carlino , Victoria Atkinson , Jonathan S. Cebon , Michael B. Jameson , Bernie M. Fitzharris , Catriona M. McNeil , Andrew G Hill , Antoni Ribas , Michael B. Atkins , John A. Thompson , Wen-Jen Hwu , F. Stephen Hodi , Alexander M. Menzies , Alexander David Guminski , Richard Kefford , Xinxin Shu , Nageatte Ibrahim , Blanca Homet Moreno , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02089685
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9545)
DOI
10.1200/JCO.2017.35.15_suppl.9545
Abstract #
9545
Poster Bd #
153
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
First Author: Georgina V. Long
Poster
2024 ASCO Annual Meeting
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.
First Author: Michael A. Postow
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson